Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial.

Breast (Edinburgh, Scotland)·2026
Same author

A model structure for describing uncertainties in benefit-risk assessment of oncology drug applications.

Frontiers in medicine·2025
Same author

Closed MCP-Mod for Pairwise Comparisons of Several Doses With a Control.

Statistics in medicine·2025
Same author

The LRRK2 p.L1795F variant causes Parkinson's disease in the European population.

NPJ Parkinson's disease·2025
Same author

18F-FDG PET findings in Parkinson's disease associated to RAB32 S71R variant.

Parkinsonism & related disorders·2025
Same author

Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?

Neuro-oncology practice·2025

Related Experiment Video

Updated: Jul 13, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Multiplicity and flexibility in clinical trials.

Werner Brannath1, Franz Koenig, Peter Bauer

  • 1Medical University of Vienna, Vienna, Austria. werner.brannath@meduniwien.ac.at

Pharmaceutical Statistics
|August 4, 2007
PubMed
Summary

Flexible clinical trial designs allow combining phases and controlling errors. Conventional analysis is possible without inflating type I error rates under specific conditions, ensuring robust drug development.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Drug Development

Background:

  • Flexible clinical trial designs offer adaptability by allowing hypothesis selection/addition during interim analyses.
  • Controlling type I error rates in flexible designs is crucial, especially when combining trials across different drug development phases.
  • Concerns exist regarding unequal patient weighting in flexible designs when reassessing sample sizes.

Purpose of the Study:

  • To review principles and methods for flexible clinical trial designs that control family-wise error rate.
  • To investigate conditions under which conventional analysis can be used without compromising type I error rates.
  • To explore flexible designs in a parallel group setting with two treatments and a common control.

Main Methods:

  • Review of existing principles and common methods for flexible designs controlling family-wise error rate.
  • Analysis of conditional type I error rates for new designs versus initial designs.
  • Application of principles to a parallel group design for treatment selection and sample size reassessment.

Main Results:

  • Flexible designs can integrate different clinical trial phases while maintaining type I error control.
  • Conventional analysis may be permissible without inflating type I error if conditional error rates are lower than the initial design.
  • The study identifies conditions for using conventional alpha z-tests in flexible parallel group designs.

Conclusions:

  • Flexible clinical trial designs are valuable for drug development, offering adaptability and error control.
  • Careful consideration of conditional type I error rates allows for the use of conventional statistical methods.
  • The findings support the use of flexible designs with conventional analysis in specific clinical trial scenarios.